SCHEMBL4256510

SCHEMBL4256510

NC(=O)c1ccc(Br)cc1Cl.O=S(=O)(O)/C=C/c1cccs1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.42
CA12 O43570 1/20 0.39
CA9 Q16790 1/20 0.39
LMNA P02545 3/20 0.39
PTGS1 P23219 1/20 0.38
PTGS2 P35354 1/20 0.38
SMN1; SMN2 Q16637 4/20 0.37
ALDH1A1 P00352 2/20 0.37
GAA P10253 1/20 0.37
HTT P42858 1/20 0.37
FLT1 P17948 1/20 0.37
FLT4 P35916 1/20 0.37
KDR P35968 1/20 0.37
NPC1 O15118 3/20 0.37
RAB9A P51151 2/20 0.37
HCAR2 Q8TDS4 1/20 0.37
DGAT1 O75907 1/20 0.37
NFKB1 P19838 1/20 0.37
NFKB2 Q00653 1/20 0.37
RELA Q04206 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4255224 0.88 LMNA (0.48) MAPTLMNAPTGS1PTGS2SMN1; SMN2
SCHEMBL4256748 0.87 MAPT (0.44) MAPTCA12CA9LMNAPTGS1
SCHEMBL4261217 0.86 LMNA (0.39) MAPTLMNAPTGS1PTGS2SMN1; SMN2
SCHEMBL27738949 0.81 CA12 (0.43) MAPTCA12CA9LMNASMN1; SMN2
SCHEMBL5417556 0.81 CA12 (0.43) MAPTCA12CA9LMNASMN1; SMN2
SCHEMBL4260434 0.81 MAPT (0.38) MAPTLMNASMN1; SMN2ALDH1A1GAA
SCHEMBL4255235 0.81 CYP1A2 (0.40) MAPTLMNAPTGS1PTGS2SMN1; SMN2
SCHEMBL4256513 0.81 FLT1 (0.49) MAPTLMNASMN1; SMN2ALDH1A1FLT1
SCHEMBL4256507 0.81 FLT1 (0.49) MAPTLMNASMN1; SMN2ALDH1A1FLT1
SCHEMBL4256612 0.81 LMNA (0.46) MAPTLMNAPTGS1PTGS2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1904471-B1 HETEROARYLETHENYL DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS HOFFMANN LA ROCHE (CH) 2009-10-21 EP claimed
US-7208506-B2 Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents HOFFMANN-LA ROCHE INC. (US) 2007-04-24 US claimed
US-20070010564-A1 Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents HOFFMANN-LA ROCHE INC. 2007-01-11 US claimed
EP-1904471-B1 HETEROARYLETHENYL DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS HOFFMANN LA ROCHE (CH) 2009-10-21 EP disclosed
US-7208506-B2 Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents HOFFMANN-LA ROCHE INC. (US) 2007-04-24 US disclosed
US-20070010564-A1 Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents HOFFMANN-LA ROCHE INC. 2007-01-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070010564-A1 Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents CYP3A43, CYP1A1, CYP3A5 MAPT 4626/4885CA12 4435/4885CA9 3920/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.